# A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

> **NCT07549581** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Schizophrenia
- Major Depressive Disorder (MDD)
- Bipolar Disorder

## Interventions

- **DRUG:** SEP-380135
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07549581
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-07
- **Primary completion:** 2025-09-12
- **Final completion:** 2025-09-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549581, "A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07549581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*